Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression

• Published in: Biomarker research Vol. 12; no. 1; p. 48
• Main Authors: Tang, Junjie, Liu, Yaoming, Wang, Yinghao, Zhang, Zhihui, Nie, Jiahe, Wang, Xinyue, Ai, Siming, Li, Jinmiao, Gao, Yang, Li, Cheng, Cheng, Chao, Su, Shicai, Chen, Shuxia, Zhang, Ping, Lu, Rong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.05.2024; BioMed Central; BMC
• Subjects: Analysis; Antibodies; AZD3965; Bioenergetics; Cancer; Cancer metabolism; Cancer therapies; Care and treatment; Cell growth; Cell viability; Datasets; Development and progression; DNA sequencing; Energy metabolism; Enucleation; Eye; Gene expression; Genetic aspects; Glycolysis; Health aspects; Hypoxia; Malignancy; Metabolic pathways; Metabolism; Monocarboxylate transporter 1; Nucleotide sequencing; Optic nerve; Penicillin; Retinoblastoma; Software; Transcriptomics; Tumors; China; United States > US; Cancer metabolism; Retinoblastoma; Monocarboxylate transporter 1; AZD3965
• ISSN: 2050-7771; 2050-7771
• DOI: 10.1186/s40364-024-00596-8

Tumors exhibit metabolic heterogeneity, influencing cancer progression. However, understanding metabolic diversity in retinoblastoma (RB), the primary intraocular malignancy in children, remains limited. The metabolic landscape of RB was constructed based on single-cell transcriptomic sequencing from 11 RB and 5 retina samples. Various analyses were conducted, including assessing overall metabolic activity, metabolic heterogeneity, and the correlation between hypoxia and metabolic pathways. Additionally, the expression pattern of the monocarboxylate transporter (MCT) family in different cell clusters was examined. Validation assays of MCT1 expression and function in RB cell lines were performed. The therapeutic potential of targeting MCT1 was evaluated using an orthotopic xenograft model. A cohort of 47 RB patients was analyzed to evaluate the relationship between MCT1 expression and tumor invasion. Distinct metabolic patterns in RB cells, notably increased glycolysis, were identified. This metabolic heterogeneity correlated closely with hypoxia. MCT1 emerged as the primary monocarboxylate transporter in RB cells. Disrupting MCT1 altered cell viability and energy metabolism. In vivo studies using the MCT1 inhibitor AZD3965 effectively suppressed RB tumor growth. Additionally, a correlation between MCT1 expression and optic nerve invasion in RB samples suggested prognostic implications. This study enhances our understanding of RB metabolic characteristics at the single-cell level, highlighting the significance of MCT1 in RB pathogenesis. Targeting MCT1 holds promise as a therapeutic strategy for combating RB, with potential prognostic implications.